Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) and Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Insider & Institutional Ownership
27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 0.9% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Actinium Pharmaceuticals and Spyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Actinium Pharmaceuticals | N/A | -100.85% | -47.89% |
| Spyre Therapeutics | N/A | -35.97% | -27.67% |
Earnings & Valuation
This table compares Actinium Pharmaceuticals and Spyre Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Actinium Pharmaceuticals | $35.09 million | 1.34 | -$48.82 million | $0.36 | 4.14 |
| Spyre Therapeutics | N/A | N/A | -$155.20 million | ($2.74) | -36.27 |
Actinium Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Actinium Pharmaceuticals has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 3.24, indicating that its share price is 224% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Actinium Pharmaceuticals and Spyre Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Actinium Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| Spyre Therapeutics | 1 | 1 | 13 | 2 | 2.94 |
Actinium Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 235.57%. Spyre Therapeutics has a consensus price target of $110.53, suggesting a potential upside of 11.23%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Actinium Pharmaceuticals is more favorable than Spyre Therapeutics.
Summary
Spyre Therapeutics beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for patients with cancer, particularly blood cancers. Its approach combines cancer-targeting antibodies with radioactive isotopes intended to deliver radiation to specific cells. The company’s investigational programs include Iomab-B (apamistamab), an iodine-131-labeled antibody targeting CD45, developed as a conditioning treatment before a bone marrow transplant for certain patients with acute myeloid leukemia.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its research focuses on therapies designed to target immune pathways involved in these conditions. The company’s pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin α4β7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development.
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
